First-in human, phase 1, dose-escalation pharmacokinetic and pharmacodynamic study of the oral dual PI3K and mTORC1/2 inhibitor PQR309 in patients with advanced solid tumors (SAKK 67/13)

Wicki, A; Brown, N; Xyrafas, A; Bize, V; Hawle, H; Berardi, S; Cmiljanovic, N; Cmiljanovic, V; Stumm, M; Dimitrijevic, S; Herrmann, R; Pretre, V; Ritschard, R; Tzankov, A; Hess, V; Childs, A; Hierro, C; Rodon, J; Hess, D; Joerger, M; von Moos, R; Ses

Wicki, A (reprint author), Univ Hosp Basel, Div Oncol, Petersgraben 4, CH-4031 Basel, Switzerland.; Wicki, A (reprint author), Univ Hosp Basel, Dept Biomed, Petersgraben 4, CH-4031 Basel, Switzerland.

EUROPEAN JOURNAL OF CANCER, 2018; 96 (): 6

Abstract

Background: PQR309 is an orally bioavailable, balanced panephosphatidylinositol-kinase (PI3K), mammalian target of rapamycin (mTOR) C1 and mTORC2 inhi......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索